J&J Drug Slows Prostate Cancer Spread by 58%: Trial

Johnson & Johnson's drug Zytiga slowed the growth of prostate cancer in a clinical trial of men who hadn't undergone chemotherapy.

Johnson & Johnson's drug Zytiga slowed the growth of prostate cancer in a clinical trial of men who hadn't undergone chemotherapy.

EP Vantage submits:Avastin’s seemingly inevitable rise to becoming the top-selling drug in the world could be under threat. Roche (RHHBY.PK) reported results Friday of a phase III trial in prostate cancer showing that the monoclonal antibody did not meet its primary endpoint of extending overall survival.

M.E. Garza submits: BioSante Pharmaceuticals (BPAX) announced Monday that the FDA's clinical hold on the GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been lifted by FDA, but will that news be enough to get investors to buy-in and hold on to shares?

The Burrill Report submits: By Michael Fitzhugh

WASHINGTON (AP) -- Scientists for the Food and Drug Administration say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects....

WASHINGTON — Scientists for the Food and Drug Administration say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects.

By Bryce Istvan:Xgeva, part of the Denosumab family, is Amgen’s (AMGN) latest bone related drug. Its current indication is for the treatment of skeletal related events (SREs) caused by bone metastases in all cancers excluding multiple myelomas.